|
1
|
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation.
|
Science
|
2010
|
9.61
|
|
2
|
The survival benefits of AIDS treatment in the United States.
|
J Infect Dis
|
2006
|
7.08
|
|
3
|
The lifetime cost of current human immunodeficiency virus care in the United States.
|
Med Care
|
2006
|
5.87
|
|
4
|
Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States.
|
Ann Intern Med
|
2013
|
4.43
|
|
5
|
Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.
|
Ann Intern Med
|
2011
|
4.21
|
|
6
|
HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness.
|
Clin Infect Dis
|
2009
|
3.89
|
|
7
|
Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202.
|
J Infect Dis
|
2011
|
3.86
|
|
8
|
Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial.
|
Ann Intern Med
|
2004
|
2.92
|
|
9
|
Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials.
|
Clin Infect Dis
|
2014
|
2.65
|
|
10
|
Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy.
|
Circulation
|
2008
|
2.64
|
|
11
|
Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection.
|
Am J Med
|
2003
|
2.48
|
|
12
|
Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis.
|
Arthritis Rheum
|
2007
|
2.37
|
|
13
|
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.
|
N Engl J Med
|
2015
|
2.17
|
|
14
|
Use of a serum beta-glucan assay for diagnosis of HIV-related Pneumocystis jiroveci pneumonia in patients with negative microscopic examination results.
|
Clin Infect Dis
|
2008
|
2.10
|
|
15
|
Potential savings by reduced CD4 monitoring in stable patients with HIV receiving antiretroviral therapy.
|
JAMA Intern Med
|
2013
|
2.10
|
|
16
|
Untreated HIV: harmful even at high CD4 cell counts.
|
Lancet
|
2010
|
2.01
|
|
17
|
Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients.
|
Clin Infect Dis
|
2006
|
2.01
|
|
18
|
Isolated antibody to hepatitis B core antigen in human immunodeficiency virus type-1-infected individuals.
|
Clin Infect Dis
|
2003
|
1.89
|
|
19
|
Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data.
|
Ann Intern Med
|
2014
|
1.75
|
|
20
|
Cost-effectiveness of genotype testing for primary resistance in Brazil.
|
J Acquir Immune Defic Syndr
|
2015
|
1.73
|
|
21
|
Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system.
|
J Acquir Immune Defic Syndr
|
2010
|
1.70
|
|
22
|
A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results.
|
J Acquir Immune Defic Syndr
|
2013
|
1.68
|
|
23
|
Editorial commentary: can we break the habit of routine CD4 monitoring in HIV care?
|
Clin Infect Dis
|
2013
|
1.66
|
|
24
|
Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution.
|
Clin Infect Dis
|
2003
|
1.62
|
|
25
|
The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV.
|
AIDS
|
2008
|
1.59
|
|
26
|
Renal safety of tenofovir disoproxil fumarate.
|
AIDS Read
|
2007
|
1.58
|
|
27
|
Predictive value of polymerase chain reaction of cerebrospinal fluid for detection of Epstein-Barr virus to establish the diagnosis of HIV-related primary central nervous system lymphoma.
|
Clin Infect Dis
|
2004
|
1.57
|
|
28
|
Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial.
|
Clin Infect Dis
|
2007
|
1.57
|
|
29
|
Routine human immunodeficiency virus testing: an economic evaluation of current guidelines.
|
Am J Med
|
2005
|
1.56
|
|
30
|
Retroviral rebound syndrome with fatal outcome after discontinuation of antiretroviral therapy.
|
Clin Infect Dis
|
2005
|
1.45
|
|
31
|
Longitudinal analysis of clinical markers following antiretroviral therapy initiated during acute or early HIV type 1 infection.
|
Clin Infect Dis
|
2006
|
1.43
|
|
32
|
Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s.
|
Clin Infect Dis
|
2011
|
1.40
|
|
33
|
Pharmacokinetic interactions between ritonavir-boosted darunavir and NNRTIs: a report of 3 cases.
|
AIDS Read
|
2008
|
1.40
|
|
34
|
Predicting virologic failure in an HIV clinic.
|
Clin Infect Dis
|
2010
|
1.39
|
|
35
|
Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks.
|
AIDS Res Hum Retroviruses
|
2012
|
1.35
|
|
36
|
Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir.
|
AIDS
|
2012
|
1.34
|
|
37
|
Test performance of blood beta-glucan for Pneumocystis jirovecii pneumonia in patients with AIDS and respiratory symptoms.
|
AIDS
|
2013
|
1.23
|
|
38
|
A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results.
|
J Acquir Immune Defic Syndr
|
2014
|
1.22
|
|
39
|
Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults.
|
Arch Intern Med
|
2002
|
1.21
|
|
40
|
Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection.
|
PLoS One
|
2010
|
1.21
|
|
41
|
HIV and syphilis coinfection: trends and interactions.
|
AIDS Clin Care
|
2003
|
1.15
|
|
42
|
Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies.
|
J Infect Dis
|
2005
|
1.14
|
|
43
|
Treatment for primary HIV infection: projecting outcomes of immediate, interrupted, or delayed therapy.
|
J Acquir Immune Defic Syndr
|
2002
|
1.13
|
|
44
|
Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients.
|
J Infect Dis
|
2002
|
1.07
|
|
45
|
Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results.
|
J Acquir Immune Defic Syndr
|
2016
|
1.07
|
|
46
|
Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS clinical trials group A5224s, a substudy of ACTG A5202.
|
J Acquir Immune Defic Syndr
|
2014
|
1.06
|
|
47
|
Effectiveness of antiretroviral therapy after protease inhibitor failure: an analytic overview.
|
Clin Infect Dis
|
2004
|
1.03
|
|
48
|
Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202.
|
J Infect Dis
|
2012
|
0.99
|
|
49
|
Metabolic and cardiovascular complications in HIV-infected patients: new challenges for a new age.
|
J Infect Dis
|
2012
|
0.98
|
|
50
|
HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status.
|
J Infect Dis
|
2012
|
0.96
|
|
51
|
When to start antiretroviral therapy--ready when you are?
|
N Engl J Med
|
2009
|
0.93
|
|
52
|
Fragility fractures in HIV-infected patients: need for better understanding of diagnosis and management.
|
J Int Assoc Physicians AIDS Care (Chic)
|
2004
|
0.91
|
|
53
|
Male sexual dysfunction associated with antiretroviral therapy.
|
J Acquir Immune Defic Syndr
|
2002
|
0.91
|
|
54
|
Low prevalence of ongoing hepatitis B viremia in HIV-positive individuals with isolated antibody to hepatitis B core antigen.
|
J Acquir Immune Defic Syndr
|
2003
|
0.89
|
|
55
|
Cost-effectiveness analysis of UGT1A1 genetic testing to inform antiretroviral prescribing in HIV disease.
|
Antivir Ther
|
2012
|
0.88
|
|
56
|
Impact of randomized antiretroviral therapy initiation on glucose metabolism.
|
AIDS
|
2014
|
0.86
|
|
57
|
Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density.
|
AIDS
|
2013
|
0.85
|
|
58
|
Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine.
|
J Acquir Immune Defic Syndr
|
2014
|
0.84
|
|
59
|
FDA approval: maraviroc.
|
AIDS Clin Care
|
2007
|
0.84
|
|
60
|
Cost-effectiveness of adding an agent that improves immune responses to initial antiretroviral therapy (ART) in HIV-infected patients: guidance for drug development.
|
HIV Clin Trials
|
2012
|
0.84
|
|
61
|
Beta-glucan for Pneumocystis pneumonia diagnosis in persons with AIDS: authors' reply.
|
AIDS
|
2013
|
0.83
|
|
62
|
Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202.
|
J Infect Dis
|
2012
|
0.83
|
|
63
|
Updated DHHS treatment guidelines.
|
AIDS Clin Care
|
2006
|
0.83
|
|
64
|
Antiretroviral resistance associated with supervised treatment interruptions in treated acute HIV infection.
|
AIDS
|
2003
|
0.81
|
|
65
|
Assessing risk for cardiovascular disease in patients with human immunodeficiency virus: Why it matters.
|
Circulation
|
2010
|
0.81
|
|
66
|
HSV-1 encephalitis complicated by cerebral hemorrhage in an HIV-positive person.
|
AIDS Read
|
2009
|
0.80
|
|
67
|
Reductions in Plasma Cystatin C After Initiation of Antiretroviral Therapy Are Associated With Reductions in Inflammation: ACTG A5224s.
|
J Acquir Immune Defic Syndr
|
2015
|
0.79
|
|
68
|
Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202.
|
J Antimicrob Chemother
|
2014
|
0.79
|
|
69
|
Assessing the performance of a computer-based policy model of HIV and AIDS.
|
PLoS One
|
2010
|
0.79
|
|
70
|
Treating morphologic and metabolic complications in HIV-infected patients on antiretroviral therapy. A consensus statement of an advisory committee of the International Association of Physicians in AIDS Care.
|
IAPAC Mon
|
2005
|
0.78
|
|
71
|
FDA approval: darunavir.
|
AIDS Clin Care
|
2006
|
0.77
|
|
72
|
A Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil fumarate (TDF), Each Coformulated with Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results.
|
J Acquir Immune Defic Syndr
|
2017
|
0.76
|
|
73
|
Top stories of 2004. Back to the future: lopinavir/ritonavir as "monotherapy".
|
AIDS Clin Care
|
2005
|
0.76
|
|
74
|
Antiretroviral therapy for treatment-naïve patients: a review of recent literature and the updated guidelines.
|
Curr Infect Dis Rep
|
2009
|
0.76
|
|
75
|
Removing legal barriers to high-quality care for HIV-infected patients.
|
N Engl J Med
|
2012
|
0.76
|
|
76
|
Access to medications and medical care after participation in HIV clinical trials: a systematic review of trial protocols and informed consent documents.
|
HIV Clin Trials
|
2009
|
0.75
|
|
77
|
Maraviroc for treatment-naive patients with HIV-1 infection: is the glass half empty or half full?
|
J Infect Dis
|
2010
|
0.75
|
|
78
|
Prevention of HIV-1 transmission with postexposure prophylaxis after inadvertent infected blood transfusion.
|
AIDS
|
2014
|
0.75
|
|
79
|
Antiretroviral therapy: now "it just works".
|
Clin Infect Dis
|
2011
|
0.75
|
|
80
|
Projected survival gains from revising state laws requiring written opt-in consent for HIV testing.
|
J Gen Intern Med
|
2011
|
0.75
|
|
81
|
Prioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the US.
|
HIV Clin Trials
|
2015
|
0.75
|
|
82
|
Report from the 13th retrovirus conference. Vicriviroc less effective than efavirenz in treatment-naive patients.
|
AIDS Clin Care
|
2006
|
0.75
|
|
83
|
Current state and limitations of daily oral therapy for treatment.
|
Curr Opin HIV AIDS
|
2015
|
0.75
|
|
84
|
Meeting notes from the 3rd IAS Conference. Advances in the treatment of hepatitis/HIV coinfection.
|
AIDS Clin Care
|
2005
|
0.75
|
|
85
|
Report from the 14th Retrovirus Conference. Treatment options for antiretroviral-naive patients.
|
AIDS Clin Care
|
2007
|
0.75
|
|
86
|
Meeting notes from ICAAC. Choosing the right HCV-coinfected patients to treat.
|
AIDS Clin Care
|
2005
|
0.75
|
|
87
|
Report from the 13th retrovirus conference. Should we be starting treatment earlier?
|
AIDS Clin Care
|
2006
|
0.75
|
|
88
|
Lower dose of ritonavir approved for use with fosamprenavir.
|
AIDS Clin Care
|
2007
|
0.75
|
|
89
|
Meeting report from the XV International AIDS Conference. Structured treatment interruption and other novel treatment strategies.
|
AIDS Clin Care
|
2004
|
0.75
|
|
90
|
Antiretroviral rounds. Suppressed but with side effects--now what?
|
J Watch AIDS Clin Care
|
2010
|
0.75
|
|
91
|
Meeting report from the XV International AIDS Conference. New drugs.
|
AIDS Clin Care
|
2004
|
0.75
|
|
92
|
Report from the 2008 joint ICAAC/IDSA meeting. More data on abacavir/3TC.
|
AIDS Clin Care
|
2008
|
0.75
|
|
93
|
Meeting notes from ICAAC. D-D4FC (Reverset): further data on treatment-experienced patients.
|
AIDS Clin Care
|
2005
|
0.75
|
|
94
|
A single case of cure?
|
AIDS Clin Care
|
2008
|
0.75
|
|
95
|
Roundtable. Who should be providing HIV care?
|
AIDS Clin Care
|
2006
|
0.75
|
|
96
|
CLINICAL PROBLEM-SOLVING. On the Nose.
|
N Engl J Med
|
2015
|
0.75
|
|
97
|
Report from the XVI International AIDS Conference. Preexposure prophylaxis studies move forward.
|
AIDS Clin Care
|
2006
|
0.75
|
|
98
|
Report from the 16th Conference on Retroviruses and Opportunistic Infections. Concomitant HIV/TB treatment improves survival.
|
J Watch AIDS Clin Care
|
2009
|
0.75
|
|
99
|
XVI International AIDS Conference: Part 1.
|
AIDS Read
|
2006
|
0.75
|
|
100
|
Report from the 5th IAS Conference on HIV Pathogenesis Treatment and Prevention. Abacavir and CVD--again.
|
J Watch AIDS Clin Care
|
2009
|
0.75
|
|
101
|
Early ART in the setting of acute OIs. Major trials support this approach, but the strategy is not without risk.
|
J Watch AIDS Clin Care
|
2010
|
0.75
|
|
102
|
AZT or tenofovir for patients with the K65R mutation?
|
J Watch AIDS Clin Care
|
2010
|
0.75
|
|
103
|
Report from the 5th IAS Conference on HIV Pathogenesis Treatment and Prevention. Nevirapine vs. boosted atazanavir--the ARTEN Study.
|
J Watch AIDS Clin Care
|
2009
|
0.75
|
|
104
|
Report from the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy.
|
AIDS Clin Care
|
2007
|
0.75
|
|
105
|
PIs may lead to premature delivery.
|
J Watch AIDS Clin Care
|
2011
|
0.75
|
|
106
|
Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants.
|
Ther Drug Monit
|
2017
|
0.75
|
|
107
|
Tenofovir/FTC approved for PrEP...but issues remain regarding implementation.
|
J Watch AIDS Clin Care
|
2012
|
0.75
|
|
108
|
Report from the 2008 joint ICAAC/IDSA meeting. Bevirimat: predictors of response.
|
AIDS Clin Care
|
2008
|
0.75
|
|
109
|
Getting started with your HIV care.
|
Posit Aware
|
2014
|
0.75
|
|
110
|
Report from the 2008 joint ICAAC/IDSA meeting. Maraviroc vs. efavirenz: a reanalysis of MERIT.
|
AIDS Clin Care
|
2008
|
0.75
|
|
111
|
Top stories of 2008. Newer drugs strikingly effective when given together.
|
AIDS Clin Care
|
2009
|
0.75
|
|
112
|
Report from the 12th Retrovirus Conference. Resistance.
|
AIDS Clin Care
|
2005
|
0.75
|
|
113
|
Comparative trial of Maraviroc vs. Tenofovir/FTC halted.
|
J Watch AIDS Clin Care
|
2013
|
0.75
|
|
114
|
Select updates from the 16th CROI: treatment-related cardiovascular risk, pharmacokinetic issues, and interleukin-2 use.
|
AIDS Read
|
2009
|
0.75
|
|
115
|
Report from the 11th conference on retroviruses and opportunistic infections. New drugs.
|
AIDS Clin Care
|
2004
|
0.75
|
|
116
|
Meeting notes from ICAAC. NRTI-only regimens: making a comeback?
|
AIDS Clin Care
|
2005
|
0.75
|
|
117
|
Meeting notes from ICAAC. Tenofovir + ddI: a combination to avoid.
|
AIDS Clin Care
|
2005
|
0.75
|
|
118
|
Report from the 15th Retrovirus Conference. Etravirine resistance: baseline prevalence and proposed criteria for "vircotype".
|
AIDS Clin Care
|
2008
|
0.75
|
|
119
|
Report from the 12th Retrovirus Conference. New drugs.
|
AIDS Clin Care
|
2005
|
0.75
|
|
120
|
Darunavir now approved for use in treatment-naive patients.
|
AIDS Clin Care
|
2008
|
0.75
|
|
121
|
Report on the XIV International AIDS Conference.
|
AIDS Clin Care
|
2002
|
0.75
|
|
122
|
Report from the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy.
|
AIDS Clin Care
|
2006
|
0.75
|
|
123
|
A nay vote for early ART in patients with cryptococcal meningitis.
|
J Watch AIDS Clin Care
|
2010
|
0.75
|
|
124
|
Report from the 17th Conference on Retroviruses and Opportunistic Infections. Non-AIDS-related adverse effects of HIV and its treatment.
|
J Watch AIDS Clin Care
|
2010
|
0.75
|
|
125
|
New HCV treatments look promising for HIV/HCV-coinfected patients.
|
J Watch AIDS Clin Care
|
2012
|
0.75
|
|
126
|
Top stories of 2007.
|
AIDS Clin Care
|
2008
|
0.75
|
|
127
|
Report from the 17th Conference on Retroviruses and Opportunistic Infections. Transmitted HIV-drug resistance in the U.S.
|
J Watch AIDS Clin Care
|
2010
|
0.75
|
|
128
|
Meeting report. Report from ICAAC.
|
AIDS Clin Care
|
2006
|
0.75
|
|
129
|
Report from the Tenth Retrovirus Conference. Comparing efavirenz and nevirapine: the 2NN study.
|
AIDS Clin Care
|
2003
|
0.75
|
|
130
|
Revised package insert for atazanavir.
|
AIDS Clin Care
|
2008
|
0.75
|
|
131
|
Antiretroviral rounds. The ABCs of LGV.
|
AIDS Clin Care
|
2005
|
0.75
|
|
132
|
Preventing and treating HIV-related OIs--updated guidelines.
|
AIDS Clin Care
|
2008
|
0.75
|
|
133
|
FDA approval: tipranavir.
|
AIDS Clin Care
|
2005
|
0.75
|
|
134
|
Report from the 2008 joint ICAAC/IDSA meeting. Raltegravir vs. efavirenz in treatment-naive patients.
|
AIDS Clin Care
|
2008
|
0.75
|
|
135
|
Report from the 5th IAS Conference on HIV Pathogenesis Treatment and Prevention.
|
J Watch AIDS Clin Care
|
2009
|
0.75
|
|
136
|
Rapid fingerstick testing: a new era in HIV diagnostics.
|
AIDS Clin Care
|
2003
|
0.75
|
|
137
|
Pink plaque on the arm of a man after a trip to Mexico: cutaneous leishmaniasis.
|
Dermatol Online J
|
2015
|
0.75
|
|
138
|
Revised guidelines for the treatment of OIs.
|
AIDS Clin Care
|
2005
|
0.75
|
|
139
|
FDA approval: etravirine.
|
AIDS Clin Care
|
2008
|
0.75
|
|
140
|
Cardiovascular outcomes among HIV-infected veterans receiving atazanavir: a US national historical cohort study.
|
AIDS
|
2017
|
0.75
|
|
141
|
Report from the 2008 joint ICAAC/IDSA meeting. Darunavir and atazanavir: 96-week data from ARTEMIS and CASTLE.
|
AIDS Clin Care
|
2008
|
0.75
|
|
142
|
Report from the 18th Conference on Retroviruses and Opportunistic Infections.
|
J Watch AIDS Clin Care
|
2011
|
0.75
|
|
143
|
Report from the 17th Conference on Retroviruses and Opportunistic Infections. Randomized studies of once-daily darunavir and tenofovir/FTC + nevirapine.
|
J Watch AIDS Clin Care
|
2010
|
0.75
|
|
144
|
One pill, once daily: now an option for HIV patients.
|
AIDS Clin Care
|
2006
|
0.75
|
|
145
|
Report from the 2008 joint ICAAC/IDSA meeting. Early ART and overall survival.
|
AIDS Clin Care
|
2008
|
0.75
|
|
146
|
Special feature. Year in review 2011.
|
J Watch AIDS Clin Care
|
2012
|
0.75
|
|
147
|
XVI International AIDS Conference: Part 2.
|
AIDS Read
|
2006
|
0.75
|
|
148
|
Report from the Tenth Retrovirus Conference. New drugs.
|
AIDS Clin Care
|
2003
|
0.75
|